Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.58 |
| ▸ | CA2 | P00918 | 15/20 | 0.58 |
| ▸ | CA12 | O43570 | 13/20 | 0.58 |
| ▸ | CA7 | P43166 | 9/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 9/20 | 0.58 |
| ▸ | CA6 | P23280 | 8/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28574241 | 0.84 | CA1 (0.60) | CA1CA2CA12CA7CA13 | |
| Hydrochloric Acid SCHEMBL7550418 | 0.83 | GSK3B (0.50) | CA1CA2CA12CA7CA13 | |
| SCHEMBL7550413 | 0.83 | GSK3B (0.50) | CA1CA2CA12CA7CA13 | |
| SCHEMBL10944333 | 0.83 | GSK3B (0.50) | CA1CA2CA12CA7CA13 | |
| SCHEMBL7914241 | 0.83 | CA1 (0.58) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1185507 | 0.83 | CA1 (0.58) | CA1CA2CA12CA7CA13 | |
| SCHEMBL7914157 | 0.83 | CA2 (0.58) | CA1CA2CA12CA7CA13 | |
| SCHEMBL11537069 | 0.80 | CA1 (0.59) | CA1CA2CA12CA7CA13 | |
| SCHEMBL7913940 | 0.80 | CA1 (0.64) | CA1CA2CA12CA7CA13 | |
| SCHEMBL9409741 | 0.79 | GSK3B (0.70) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20170305917-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-9732085-B2 | Pyridinone and pyrimidinone derivatives as factor Xia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20150152112-A1 | COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2794597-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
| EP-1001934-B1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6300363-B1 | USEFUL IN THE TREATMENT OR ALLEVIATION OF INFLAMMATION AND OTHER INFLAMMATION ASSOCIATED DISORDERS IN MAMMALS | PFIZER INC. | 2001-10-09 | — | — | US | disclosed |
| US-6214882-B1 | Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof | SYNTHELABO (FR) | 2001-04-10 | — | — | US | disclosed |
| EP-1001934-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999005104-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998008830-A1 | THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152112-A1 | COMPOUNDS | F11, F12, F10 | CA1 465/4885CA2 617/4885CA12 733/4885 |
| US-20170305917-A1 | COMPOUNDS | F11, F12, F10 | CA1 465/4885CA2 617/4885CA12 733/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | CA1 3552/4885CA2 2927/4885CA12 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.